MOTS-c

It is like a fitness-tracker reading that reliably climbs when you exercise and dips when you are metabolically unwell. That makes it a great dashboard light but nobody has yet shown that forcing the needle up with a syringe makes the engine run better. In mice it does; in humans we have only watched the dial, not yet turned it.

Encoded within the mitochondrial 12S rRNA, MOTS-c is a 16-amino-acid mitochondrial-derived peptide that interferes with the folate one-carbon cycle and de novo purine synthesis, causing AICAR accumulation and activating the cellular energy sensor AMPK. This promotes glucose uptake via GLUT4 and a metabolic state resembling exercise. Under metabolic stress it translocates to the nucleus, where it regulates stress-response and antioxidant gene programmes including NRF2-linked pathways. Skeletal muscle is the principal target tissue.

Research contexts. Not proven uses, and not recommendations.

Genuine human evidence is observational, not interventional. Studies show MOTS-c is induced in skeletal muscle and rises in the circulation after acute exercise, and that lower circulating levels correlate with insulin-resistance markers (HOMA-IR, HbA1c) and with type 2 diabetes, PCOS and other metabolic conditions. These establish MOTS-c as a biomarker and plausible target but do not show that administering it benefits people. As of mid-2026 the first registered controlled interventional efficacy trial (Phase 2a, NCT07505745, prediabetes with overweight/obesity) started recruiting in February 2026 and has not reported results. No efficacy endpoint has yet been met in any human trial.

• !Human efficacy is unproven. To date the only human data are observational or biomarker studies; no completed controlled trial shows benefit from administering it.
• !Everything sold to the public is unlicensed research chemical material labelled 'not for human consumption'. It is not a medicine and has no MHRA marketing authorisation.
• !Grey-market purity, sterility, dose accuracy and endotoxin contamination are real risks with injectable research peptides. Injection itself carries infection and abscess risk.
• !Long-term safety in humans is essentially unknown. Immunogenicity and the effects of chronic supraphysiological dosing are unstudied.
• !Marketing routinely extrapolates striking mouse longevity and metabolic data directly to humans, a classic overclaim the actual evidence does not support.
• !Circulating MOTS-c measurement by antibody has been debated within the science, complicating the biomarker literature.

Not a licensed medicine in the UK. MOTS-c has no MHRA marketing authorisation and is not approved for any indication. It is an investigational or preclinical agent. It is not a controlled drug, but selling or supplying it for human use would breach the Human Medicines Regulations 2012; vendors therefore market it as a research chemical or reference standard labelled not for human consumption. There is no legitimate UK prescription route. As an endogenous metabolic or exercise-mimetic peptide it also attracts anti-doping interest; anyone subject to sport testing should check current WADA guidance. For the general public the key fact is that it is an unlicensed, unregulated product.

• NCT07505745· Phase 2a· Recruiting (started February 2026); no efficacy results reported

  MOTS-c (MDP) subcutaneous injection in insulin resistance, prediabetes and overweight/obesity

  Randomised, double-blind, placebo-controlled; primary endpoint OGTT-derived insulin sensitivity (Matsuda index); secondary endpoints include HbA1c, fasting/2-hour glucose and safety/immunogenicity.

1. 01
   The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance — Lee C, Zeng J, Drew BG, et al., Cell Metabolism (2015)

   Landmark discovery paper: identifies MOTS-c, AMPK activation via the folate cycle, and metabolic effects in mice.

2. 02
   The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Kim KH, Son JM, Benayoun BA, Lee C, Cell Metabolism (2018)

   Establishes MOTS-c nuclear translocation and its role as an AMPK-dependent transcriptional regulator of stress-response genes.

3. 03
   MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis — Reynolds JC, Lai RW, Woodhead JST, et al., Nature Communications (2021)

   Shows exercise induces endogenous MOTS-c in human muscle and circulation; intermittent administration improves physical capacity in aged mice.

4. 04
   MOTS-c: review of mechanism and the preclinical-versus-human evidence gap for the mitochondrial-derived peptide, PubMed (review literature) (2022)

   Representative review summarising mechanism and the gap between striking preclinical data and limited human evidence. PubMed search link given rather than a single identifier to avoid citing an uncertain ID.

5. 05
   MOTS-c (MDP), subcutaneous, in insulin resistance / prediabetes with overweight/obesity (Phase 2a) (2025)

   First registered controlled interventional human efficacy trial; OGTT-derived Matsuda index primary endpoint; no results reported at time of writing.